[CAS NO. 394730-60-0] Boceprevir

Name: Boceprevir
Brand: Arctom Scientific
SKU: AS254814

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [394730-60-0]

Store

Catalog

AS254814

Brand

Arctom Scientific

CAS

394730-60-0

DESCRIPTION [394730-60-0]

Overview

MDL	MFCD22208555
Molecular Weight	519.68
Molecular Formula	C27H45N5O5
SMILES	O=C(N1[C@@H]([C@@]2([H])C(C)([C@]2(C1)[H])C)C(NC(C(C(N)=O)=O)CC3CCC3)=O)[C@@H](NC(NC(C)(C)C)=O)C(C)(C)C

For research use only. We do not sell to patients.

26 Publications Citing Use of MCE

Summary

Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K _i of 14 nM in both enzyme assay and an EC ₉₀ of 350 nM in cell-based replicon assay ^[1] ^[2] ^[3] ^[4] ^[5] . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity ^[6] .

IC50 & Target

Ki: 14 nM (HCV NS3 protease) ^[1]

In Vitro

In the HCV NS3 protease continuous assay, Boceprevir (SCH 503034) has a potency of 14 nM (K _i ) average over a large number of runs. In the 72-h bicistronic subgenomic cell-based replicon assay in HuH-7 cells, the EC ₅₀ and EC ₉₀ values are determined to be 0.20 µM and 0.35 µM, respectively. Boceprevir is also found to be a very weak inhibitor of HNE (K _i =26 µM) representing a selectivity of 2200 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. The pharmacokinetic profile of Boceprevir is evaluated in several animal species. Following oral administration, Boceprevir is moderately absorbed in rats (10 mg/kg), dogs (3 mg/kg), and monkeys (3 mg/kg). Absorption is relatively rapid in dogs but slower in mice (10 mg/kg), rats, and monkeys, as evidenced by mean absorption times (MAT) ranging from 0.5 to 1.4 h. The AUC is good in dogs and rats, moderate in mouse, and low in monkeys. The absolute oral bioavailability is modest in mouse, rats, and dogs (26-34%) but low in monkeys (4%) ^[1] . Boceprevir (100 mg/kg, orally) inhibit HCV NS3/4A protease activity in triple-transgenic mice ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00959699	Merck Sharp & Dohme LLC	HIV Infections\|Hepatitis C\|HCV Infection	November 2009	Phase 2
NCT02333292	Valme University Hospital\|Hospital del SAS de Jerez\|Hospital General Universitario Elche\|Hospital La Línea de la Concepción\|Complexo Hospitalario Universitario de A Coruña\|Hospital de Figueres\|Hospital Universitario Puerto Real\|Hospital Universitario Virgen de la Victoria\|Hospital Universitario de Canarias\|Hospital General Universitario de Alicante\|Hospital Universitario Araba\|Hospital Royo Vilanova\|Hospital Universitario de Burgos\|Complejo Hospitalario Universitario de Huelva\|Hospital Universitario Reina Sofia de Cordoba\|Hospital Universitario Virgen Macarena\|Complejo Hospitalario Universitario de Vigo\|Clinica Universidad de Navarra, Universidad de Navarra\|Hospital Clinico Universitario San Cecilio\|Hospital Universitario La Fe\|Hospital General Universitario de Valencia\|Hospital Universitario Infanta Leonor\|Hospital Universitario de Gran Canaria\|Hospital General Universitario Santa Lucía\|Centro Penitenciario Alicante 1\|Hospital Regional Universitario Carlos Haya\|Hospital Virgen de la Luz\|Hospital General Universitario de Castellón\|Hospital Parc Taulí, Sabadell	Chronic Hepatitis C Infection	December 2014
NCT01597895	ViiV Healthcare\|Pfizer	Healthy	July 2012	Phase 1
NCT01657552	GlaxoSmithKline	Thrombocytopaenia	August 1, 2012	Phase 1
NCT01396005	Merck Sharp & Dohme LLC	Hepatitis C Virus	September 2011	Phase 1
NCT00705432	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	August 2008	Phase 3
NCT01425203	Merck Sharp & Dohme LLC	Chronic Hepatitis C Genotype 1	November 23, 2011	Phase 3
NCT01731301	Liver Institute of Virginia\|Merck Sharp & Dohme LLC\|Chronic Liver Disease Foundation	Chronic Hepatitis C\|End Stage Renal Disease	January 2013	Phase 4
NCT00845065	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	February 2009	Phase 3
NCT01770223	Merck Sharp & Dohme LLC	Hepatitis C	January 2014	Phase 4
NCT01482403	Hoffmann-La Roche	Hepatitis C, Chronic	November 2011	Phase 2
NCT01585584	University of Calgary\|Merck Sharp & Dohme LLC	Hepatitis C	May 2012	Phase 3
NCT01718301	Anna Cruceta\|Fundacion Clinic per a la Recerca Biomédica	Hepatitis C\|HIV Infections\|COINFECTION	March 2013	Phase 3
NCT02160080	Hu Tsung-Hui\|Chang Gung Memorial Hospital	Late Complication From Liver Transplant	January 2014	Phase 3
NCT01425190	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	January 4, 2012	Phase 1
NCT01925183	Markus Peck-Radosavljevic\|Medical University of Vienna	Hepatitis C, Chronic\|HIV	August 2013	Phase 4
NCT01909401	Indiana University\|Merck Sharp & Dohme LLC	Liver Transplantation	June 2013	Early Phase 1
NCT02118597	Hoffmann-La Roche	Hepatitis C, Chronic	May 2014
NCT01756079	Merck Sharp & Dohme LLC	Hepatitis C	February 6, 2013	Phase 4
NCT01403181	Azienda Ospedaliero-Universitaria di Parma	Chronic Hepatitis C	April 2012
NCT01181804	Merck Sharp & Dohme LLC	Hepatitis C	June 2010	Phase 1
NCT01945294	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	October 10, 2013	Phase 3
NCT00160251	Merck Sharp & Dohme LLC	Chronic Hepatitis C	September 2005	Phase 2
NCT01663922	St Stephens Aids Trust\|University of Liverpool\|University of Turin, Italy	Hepatitis C	August 2012	Phase 1
NCT01641666	Merck Sharp & Dohme LLC	Chronic Hepatitis C	May 2014	Phase 3
NCT01499498	Imperial College London	Hepatitis C	December 2012	Phase 1
NCT02204475	Merck Sharp & Dohme LLC	Hepatitis C	November 2014	Phase 3
NCT01544920	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	May 30, 2012	Phase 3
NCT02112630	Columbia University\|Merck Sharp & Dohme LLC	Hepatitis C Infection\|End Stage Renal Disease	May 2013	Not Applicable
NCT01591460	Hoffmann-La Roche	Hepatitis C, Chronic	August 2012	Phase 4
NCT01447446	Hoffmann-La Roche	Hepatitis C, Chronic	September 2011
NCT01463956	French National Agency for Research on AIDS and Viral Hepatitis\|Merck Sharp & Dohme LLC\|ANRS, Emerging Infectious Diseases	HCV Infection\|Liver Cirrhosis, Experimental	January 6, 2012	Phase 2
NCT01288417	Radboud University Medical Center\|Merck Sharp & Dohme LLC	HIV Infections\|HCV Infections	August 2011	Phase 1
NCT01446250	Debiopharm International SA	Hepatitis C	December 2011	Phase 3
NCT01023035	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	December 7, 2009	Phase 3
NCT02113631	Louis Stokes VA Medical Center	Hepatitis C, Chronic\|Cirrhosis	September 2011	Not Applicable
NCT00910624	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	June 22, 2009	Phase 3
NCT00689390	Merck Sharp & Dohme LLC	Hepatitis C, Chronic\|Hepacivirus	February 20, 2007	Phase 2\|Phase 3
NCT02758509	Parc de Salut Mar	Chronic Hepatitis C\|Cirrhosis	January 1, 2010
NCT01353911	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	June 27, 2011	Phase 2
NCT01443923	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Hepatitis\|HIV+AIDS	September 2011	Phase 4
NCT01470690	Radboud University Medical Center\|Merck Sharp & Dohme LLC	HCV Infections\|Gastric Acid-related Disorders	October 2011	Phase 1
NCT01590225	Merck Sharp & Dohme LLC	Chronic Hepatitis C	January 28, 2013	Phase 3
NCT01465516	Arrowhead Regional Medical Center	Hepatitis C Infection	November 2011
NCT01390844	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	October 21, 2011	Phase 3
NCT01653236	Theodor Bilharz Research Institute	Genotype 4 Chronic Hepatitis C Infection	December 2013	Phase 3
NCT01949168	St Vincent´s Hospital Melbourne\|Merck Sharp & Dohme LLC	Chronic Hepatitis C	September 2013	Phase 2
NCT01482767	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Hepatitis C	April 2012	Phase 3
NCT01457937	University of Modena and Reggio Emilia\|Merck Sharp & Dohme LLC	Chronic Hepatitis C\|Menopause	November 2011	Phase 3
NCT01912495	Erasmus Medical Center\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Onze Lieve Vrouwe Gasthuis\|UMC Utrecht\|University Medical Center Groningen\|Maastricht University Medical Center\|Rijnstate Hospital\|Slotervaart Hospital\|Radboud University Medical Center	Hepatitis C\|Human Immunodeficiency Virus	August 2013	Phase 2
NCT01627717	Centre hospitalier de l´Université de Montréal (CHUM)\|Université de Montréal\|McGill University Health Centre+Research Institute of the McGill University Health Centre\|Toronto General Hospital	Healthy	June 2012	Phase 1
NCT00708500	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	August 2008	Phase 3
NCT00423670	Merck Sharp & Dohme LLC	Chronic Hepatitis C	January 2007	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL ( 32.08 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9243 mL	9.6213 mL	19.2426 mL
5 mM	0.3849 mL	1.9243 mL	3.8485 mL
10 mM	0.1924 mL	0.9621 mL	1.9243 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.67 mg/mL (3.21 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 1.67 mg/mL (3.21 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1.67 mg/mL (3.21 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-

(1R,2S,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

Sch 503034

Boceprevir

EBP 520

Victrelis

Boceprevirertet